VistaGen Therapeutics Set to Join the Russell 2000® Index
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to...
News
Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the...
Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI)
Supporting data in preclinical model of drug-resistant epilepsy demonstrate seizure-freedom in 70% of the NRTX-1001 cell therapy treatment group versus...
Selecta Biosciences to Participate at the Raymond James Human Health Innovation Conference
WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated...
Jounce Therapeutics to Host Virtual R&D Day on June 23, 2021
CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery...
PharmaTher To Present At The H.C. Wainwright Psychedelics In Psychiatry And Beyond Virtual Conference
TORONTO, June 16, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage...
Apexigen and the Nordic Society of Gynaecological Oncology – Clinical Trial Unit Announce Collaborative Phase 2 Study of Sotigalimab (APX005M) in Combination Therapy for Ovarian Cancer
-Study to be conducted at multiple sites across Europe through European Network of Gynaecological Oncological Trial groups (ENGOT)-SAN CARLOS, Calif. and...
Enlivex Annouces Participation in A.G.P.’s Upcoming 2021 Virtual Summer Healthcare Symposium
Nes Ziona, Israel, June 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...
Impel NeuroPharma to Present at the Raymond James Human Health Innovation Conference
SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of...
Starton Therapeutics Phase 2 TROPIC-I Clinical Study will be First to Use Total Control Primary Endpoint in Superiority Study
STAR-OLZ for acute and delayed chemotherapy induced nausea and vomiting (CINV)PARAMUS, N.J., June 16, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics...
BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update
- NDA Filed by U.S. Food and Drug Administration (FDA) and given Priority Review for plinabulin plus G-CSF for the...
electroCore to Join Russell Microcap® Index
ROCKAWAY, NJ, June 16, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today the...
89bio to Participate in Upcoming Investor Conferences
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development...
Motus GI Announces First Patients Enrolled in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing in Patients With a History of Poor Bowel Preparation
FORT LAUDERDALE, Fla., June 16, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"),...
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
37% CR rate in 30 efficacy-evaluable patientsBOSTON, June 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical...
Adagene Announces Inclusion in FTSE Russell Indexes
SAN FRANCISCO and SUZHOU, China, June 16, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical...
Mydecine Unveils Artificial Intelligence Drug Discovery Program
Expanded A.I. and machine learning capabilities will accelerate Mydecine’s broader research and development effortsDENVER, June 16, 2021 (GLOBE NEWSWIRE) --...
Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT™ Glioblastoma Trial
AUSTIN, Texas, June 16, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel,...
Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline)
-- U.S.-Based Sites Ready to Begin Enrolling Patients, Placebo-Controlled Study Evaluating NUZYRA Efficacy at 12 Weeks of Treatment -- Potential...
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific moleculesMacroGenics provides...